Eli Lilly and Company (FRA:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 506.14B |
| Revenue (ttm) | 45.35B |
| Net Income (ttm) | 11.75B |
| Shares Out | n/a |
| EPS (ttm) | 13.02 |
| PE Ratio | 43.07 |
| Forward PE | 23.64 |
| Dividend | 5.18 (0.94%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 477 |
| Average Volume | 755 |
| Open | 568.10 |
| Previous Close | 563.20 |
| Day's Range | 562.90 - 570.40 |
| 52-Week Range | 537.40 - 888.80 |
| Beta | n/a |
| RSI | 32.65 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback. Latest Ratings for VKTX ... Full story available on Ben...
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
Viking Therapeutics, Inc. VKTX is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a...
SA analyst upgrades/downgrades: TSLA, LLY, MSFT, NBIS
We're double upgrading Eli Lilly after the CEO and other insiders scoop up the slumping stock
Lilly shares rose nearly 3% in Wednesday's session.
Eli Lilly Board Member Makes $1.01M Stock Purchase
J. Erik Fyrwald pursuant to authorization on file , Board Member at Eli Lilly (NYSE: LLY), disclosed an insider purchase on August 12, based on a new SEC filing. What Happened: file made a significan...
EVP Of Eli Lilly Purchased $634K In Stock
Daniel Skovronsky , EVP at Eli Lilly (NYSE: LLY), reported an insider buy on August 12, according to a new SEC filing. What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,0...
Smart Money Move: David A Ricks Grabs $1.05M Worth Of Eli Lilly Stock
In a recent SEC filing, it was revealed that David A Ricks , President at Eli Lilly (NYSE: LLY), made a noteworthy insider purchase on August 12,. What Happened: Ricks demonstrated confidence in Eli ...
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Guggenhei...
Eli Lilly begins commercial rollout of Mounjaro pen in India
Eli Lilly insider buying from CEO and others jump amid selloff
Lilly launches Mounjaro pen in India priced at $160
Eli Lilly launched the pre-filled injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India on Wednesday, stepping up competiti...
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years
Eli Lilly (NYSE: LLY) has outperformed the market over the past 15 years by 8.92% on an annualized basis producing an average annual return of 21.42%. Currently, Eli Lilly has a market capitalization...
These Eli Lilly executives have been scooping up stock after its big drop
Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 million worth of stock in the aftermath of the selloff.
Final Trade: LLY, ULTA, AAPL, GDX
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: LLY, ULTA, AAPL, GDX
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Crude Oil Down 1%; Gevo Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Tuesday. The Dow traded up 1.04% to 44,431.01 while the NASDAQ rose 1.26% to 21,654.94. The S&P 500 also rose...
Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade)
Dow Surges 500 Points; US Core Inflation Rises To 3.1%
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 1% on Tuesday. The Dow traded up 1.14% to 44,477.20 while the NASDAQ rose 1.28% to 21,659.58. The S&P 500 also...
Eli Lilly sued in Texas over illegal kickbacks related to weight loss drugs
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients . The initiative , announced Tuesday, combines governme...
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies.
1 Reason to Buy Eli Lilly (LLY) Stock
There's a reason you might want to hold off on buying Lilly stock.
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'
On CNBC's “ Mad Money Lightning Round ,” Jim Cramer said Affirm Holdings Inc (NASDAQ: AFRM) is a buy. “It's at $72, it's going to $100,” he noted. On the earnings front, Affirm will announce its four...
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc AFRM is a buy. “It's at $72, it's going to $100,” he noted.